Canopy Growth Corporation - Common Shares (WEED)
1.5300
+0.0300 (2.00%)
TSX · Last Trade: Apr 30th, 10:20 AM EDT
Detailed Quote
| Previous Close | 1.500 |
|---|---|
| Open | 1.500 |
| Bid | 1.520 |
| Ask | 1.530 |
| Day's Range | 1.500 - 1.540 |
| 52 Week Range | 1.180 - 3.280 |
| Volume | 216,104 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,936,179 |
Chart
About Canopy Growth Corporation - Common Shares (WEED)
Canopy Growth Corp is a leading player in the cannabis industry, focusing on the production and distribution of a wide range of cannabis products. The company is engaged in cultivating and processing cannabis for both medical and recreational purposes, offering various forms such as dried flower, oils, edibles, and beverages. With a commitment to innovation, Canopy Growth invests in research and development to create high-quality products that meet consumer demands and adhere to evolving regulations. The company also emphasizes sustainability and responsible business practices, aiming to shape the future of cannabis consumption and enhance the overall experience for consumers. Read More
News & Press Releases
EQNX::TICKER_START (OTCQB:LUFFF),(CSE:HERB),(NASDAQ:TLRY),(NASDAQ:CGC),(NASDAQ:SNDL),(NASDAQ:OGI),(TSX:WEED),(CSE:SNDL) EQNX::TICKER_END
Via FinancialNewsMedia · April 30, 2026
Innovative product formats and growing global acceptance are fueling a powerful long-term growth trajectory
By MarketNewsUpdates.com · Via GlobeNewswire · April 30, 2026
420 with CNW — Trucking Industry in Grey Area as Marijuana is Reclassified Federally
A directive signed by Acting AG Todd Blanche on April 22 and put into force the next day shifts two categories of cannabis from Schedule I of the CSA to Schedule III. One includes marijuana-based medications approved by the FDA. The other applies to cannabis produced, distributed, or sold under state-issued medical licenses.
Via CannabisNewsWire · April 29, 2026
420 with CNW — Trucking Industry in Grey Area as Marijuana is Reclassified Federally
A directive signed by Acting AG Todd Blanche on April 22 and put into force the next day shifts two categories of cannabis from Schedule I of the CSA to Schedule III. One includes marijuana-based medications approved by the FDA. The other applies to cannabis produced, distributed, or sold under state-issued medical licenses.
Via Investor Brand Network · April 29, 2026
420 with CNW — California Firms Say Consumers Aren’t Interested in Low-THC Beverages
Low-dose THC drinks may be gaining shelf space in bars and retail chains, but they are not resonating with marijuana shoppers in California, according to industry representatives .
Via Investor Brand Network · April 13, 2026
420 with CNW — California Firms Say Consumers Aren’t Interested in Low-THC Beverages
Low-dose THC drinks may be gaining shelf space in bars and retail chains, but they are not resonating with marijuana shoppers in California, according to industry representatives .
Via CannabisNewsWire · April 13, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price.
By Canopy Growth Corporation · Via Business Wire · March 31, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical Cannabis Clinic in the 2025 Toronto Star’s Readers’ Choice Awards, a public vote that reflects the trust patients place in Apollo’s care.
By Canopy Growth Corporation · Via Business Wire · March 30, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel’s Co-founder, who has decided to transition out of his role.
By Canopy Growth Corporation · Via Business Wire · March 27, 2026
420 with CNW — How US Marijuana Breeders Could Protect Their IP Prior to Legalization
Veteran marijuana breeder James Loud is setting his sights on a niche that continues to grow: pre-rolls and ready-to-use joints. Over the next few years, he plans to develop plant varieties tailored for these products, with a focus on durability and consistency during storage and transport.
Via Investor Brand Network · March 26, 2026
420 with CNW — How US Marijuana Breeders Could Protect Their IP Prior to Legalization
Veteran marijuana breeder James Loud is setting his sights on a niche that continues to grow: pre-rolls and ready-to-use joints. Over the next few years, he plans to develop plant varieties tailored for these products, with a focus on durability and consistency during storage and transport.
Via CannabisNewsWire · March 26, 2026
Canopy Growth Corp (TSX:WEED) could wreck your portfolio.
Via The Motley Fool · March 16, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and MTL Cannabis Corp. (“MTL Cannabis” or “MTL”) (CSE: MTLC) (OTCQX: MTLNF) today announced the completion of the previously announced arrangement (the “Arrangement”), whereby, among other things, Canopy Growth has acquired all of the issued and outstanding common shares of MTL (the “MTL Shares”).
By Canopy Growth Corporation · Via Business Wire · March 16, 2026
420 with CNW — Study Suggests Marijuana Compounds Could Potentially Reverse Liver Disorder
Compounds derived from marijuana may offer a new direction for addressing one of the most widespread chronic liver illnesses worldwide, according to recent findings from researchers at Hebrew University of Jerusalem.
Via CannabisNewsWire · March 13, 2026
420 with CNW — Study Suggests Marijuana Compounds Could Potentially Reverse Liver Disorder
Compounds derived from marijuana may offer a new direction for addressing one of the most widespread chronic liver illnesses worldwide, according to recent findings from researchers at Hebrew University of Jerusalem.
Via Investor Brand Network · March 13, 2026
420 with CNW — What Employers Should Know About the Proposed Easing of Federal Cannabis Laws
Cannabis remains listed as a Schedule I substance under the Controlled Substances Act (CSA), a category reserved for drugs considered to have a high likelihood of misuse and no recognized medical purpose. That designation has shaped federal drug policy for decades and continues to influence workplace rules across the country.
Via CannabisNewsWire · March 2, 2026
420 with CNW — What Employers Should Know About the Proposed Easing of Federal Cannabis Laws
Cannabis remains listed as a Schedule I substance under the Controlled Substances Act (CSA), a category reserved for drugs considered to have a high likelihood of misuse and no recognized medical purpose. That designation has shaped federal drug policy for decades and continues to influence workplace rules across the country.
Via Investor Brand Network · March 2, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) is pleased to announce that shareholders of MTL Cannabis Corp. (“MTL Cannabis” or “MTL”) have voted to approve the Company’s previously announced acquisition of MTL (the “Transaction”) at a special meeting of shareholders of MTL (the “MTL Shareholders”) held February 17, 2026.
By Canopy Growth Corporation · Via Business Wire · February 18, 2026
420 with CNW — Marijuana Legalization Could Lower Daily Opioid Use
Expanding legal access to marijuana for both recreational and medical use may be linked to lower levels of daily opioid consumption among people who inject substances, according to new research led by a scholar at the Boston University School of Public Health.
Via Investor Brand Network · February 12, 2026
420 with CNW — Marijuana Legalization Could Lower Daily Opioid Use
Expanding legal access to marijuana for both recreational and medical use may be linked to lower levels of daily opioid consumption among people who inject substances, according to new research led by a scholar at the Boston University School of Public Health.
Via CannabisNewsWire · February 12, 2026
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announced its financial results for the three months ended December 31, 2025 ("Q3 FY2026"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
By Canopy Growth Corporation · Via Business Wire · February 6, 2026
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026.
By Canopy Growth Corporation · Via Business Wire · January 23, 2026
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
By Equity Insider · Via GlobeNewswire · January 29, 2026
420 with CNW — New Study Says No Science Supports Federal Categorization of Marijuana
A new scientific review is challenging the foundations of U.S. drug law, arguing that the legal system governing controlled substances no longer reflects modern scientific understanding of risk.
Via Investor Brand Network · January 22, 2026
420 with CNW — New Study Says No Science Supports Federal Categorization of Marijuana
A new scientific review is challenging the foundations of U.S. drug law, arguing that the legal system governing controlled substances no longer reflects modern scientific understanding of risk.
Via CannabisNewsWire · January 22, 2026